The role of radiation therapy in the multidisciplinary management of male breast cancer: a systematic review and meta-analysis.

breast-conserving therapy male breast cancer metanalysis post-mastectomy radiotherapy radiation therapy radiotherapy

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
23 Oct 2024
Historique:
received: 03 04 2024
revised: 10 10 2024
accepted: 14 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: aheadofprint

Résumé

Male breast cancer (MaBC) is an uncommon disease. It is generally assimilated to post-menopausal female breast cancer and treated accordingly. However, the real impact of radiation therapy, after both mastectomy and breast conservation, has yet to be established. We performed a systematic review and meta-analysis to assess the clinical impact of radiation therapy in MBC patients to support the clinical decision-making process and to inform future research. We performed a systematic search of 'male', 'breast', 'cancer', 'radiotherapy' and corresponding synonyms on PubMed/MEDLINE and EMBASE databases. We included interventional studies reporting on radiation therapy effect on overall survival (OS) in MBC patients. Reviews, editorials, letters to the editor, conference abstracts and case reports, and studies with less than 20 MaBC patients or without data on OS were excluded. We extracted relevant characteristics and outcomes for each study, including the hazard ratio (HR) for OS, after adjustment for potential confounders. We calculated an overall adjusted hazard ratio (aHR) for OS for patients receiving radiation therapy compared to those who did not. A random effect model was used. The search strategy yielded 10,260 articles. After removal of duplicates (n = 8,254), 2,006 articles remained and underwent abstract screening. A total of 168 manuscripts was selected for full text screening. After full text screening, 22 articles were included in the qualitative systematic review. Among them, 14 were included in the quantitative synthesis, reporting on 80.219 MaBC patients. A statistically significant reduction in the risk of death was observed for patients receiving radiation therapy, with a pooled aHR = 0.73 (95%CI: 0.66-0.81) for OS. Significant heterogeneity among reported aHR estimates was seen (I2=77%). A significant clinical benefit on OS has been observed when including radiation therapy in the therapeutic algorithm of patients with MaBC. These findings, which are based on retrospective studies and tumour registry reports, deserve further investigation to identify MaBC patient subgroups who most benefit from radiation therapy.

Identifiants

pubmed: 39454738
pii: S1040-8428(24)00280-4
doi: 10.1016/j.critrevonc.2024.104537
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104537

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest no conflict of interest to disclose related to the present manuscript

Auteurs

Riccardo Ray Colciago (RR)

Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Via Giacomo Venezian, 1, 23100, Milano, Italy.

Valentina Lancellotta (V)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy.

Maria Carmen De Santis (MC)

Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Via Giacomo Venezian, 1, 23100, Milano, Italy.

Elisabetta Bonzano (E)

Radiation Oncology Department, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.

Fiorenza De Rose (F)

Department of Radiation Oncology, Santa Chiara Hospital, Trento, Italy.

Eliana La Rocca (E)

Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Via Giacomo Venezian, 1, 23100, Milano, Italy.

Bruno Meduri (B)

Department of Radiation Oncology, University Hospital of Modena, Modena, Italy.

Nadia Pasinetti (N)

Radiation Oncology Department, ASST Valcamonica Esine and University of Brescia, Brescia, Italy.

Agnese Prisco (A)

Department of Radiation Oncology, University Hospital of Udine, ASUIUD - Piazzale S.M della Misericordia 15, 33100, Udine, Italy.

Alessandra Gennari (A)

Department of Translational Medicine (DIMET), University of Eastern Piedmont, Novara, Italy; Medical Oncology Department, AOU 'Maggiore della Carità', 28100 Novara, Italy.

Trine Tramm (T)

Department of Pathology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.

Serena Di Cosimo (SD)

Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Nadia Harbeck (N)

Breast Center, Department of Obstetrics & Gynecology and CCC Munich, LMU University Hospital, Munich, Germany.

Giuseppe Curigliano (G)

European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.

Philip Poortmans (P)

Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk-Antwerp, Belgium.

Icro Meattini (I)

Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy; Radiation Oncology & Breast Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

Pierfrancesco Franco (P)

Department of Translational Medicine (DIMET), University of Eastern Piedmont, Novara, Italy; Department of Radiation Oncology, 'Maggiore della Carità' University Hospital, 28100 Novara, Italy. Electronic address: pierfrancesco.franco@uniupo.it.

Classifications MeSH